$AIFF
FIREFLY NEUROSCIENCE, INC.

2024 Q4 Form 10-Q Financial Statement

#000143774924035393 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $33.00K $1.830M
YoY Change -98.32% -23.84%
Cost Of Revenue $1.227M
YoY Change -23.77%
Gross Profit $602.7K
YoY Change -23.97%
Gross Profit Margin 32.93%
Selling, General & Admin $3.423M $1.155M
YoY Change 193.4% -63.71%
% of Gross Profit 191.71%
Research & Development $878.0K
YoY Change 123.98%
% of Gross Profit
Depreciation & Amortization $52.77K
YoY Change -85.34%
% of Gross Profit 8.76%
Operating Expenses $4.301M $1.208M
YoY Change 268.66% -62.05%
Operating Profit -$4.268M -$605.5K
YoY Change 725.78% -74.68%
Interest Expense -$12.27K
YoY Change -44.35%
% of Operating Profit
Other Income/Expense, Net $5.000K $7.260K
YoY Change 60.62% 131.95%
Pretax Income -$4.289M -$811.9K
YoY Change 2760.63% -91.5%
Income Tax $0.00 -$42.59K
% Of Pretax Income
Net Earnings -$4.289M -$769.3K
YoY Change 2760.63% -91.86%
Net Earnings / Revenue -12996.97% -42.04%
Basic Earnings Per Share -$0.61
Diluted Earnings Per Share -$0.38
COMMON SHARES
Basic Shares Outstanding 8.503M 7.341M 2.013M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $682.0K
YoY Change -6.71%
Cash & Equivalents $1.230M $682.0K
Short-Term Investments
Other Short-Term Assets $3.545K
YoY Change
Inventory
Prepaid Expenses $1.349M $28.00K
Receivables $1.118M
Other Receivables $86.00K $0.00
Total Short-Term Assets $2.665M $2.067M
YoY Change -2.05% -26.25%
LONG-TERM ASSETS
Property, Plant & Equipment $72.00K $58.00K
YoY Change 7.94% -90.29%
Goodwill $1.125M
YoY Change 0.0%
Intangibles $1.109M $1.006M
YoY Change 5.66% -66.48%
Long-Term Investments
YoY Change
Other Assets $18.42K
YoY Change -76.77%
Total Long-Term Assets $2.646M $2.453M
YoY Change 4.13% -52.63%
TOTAL ASSETS
Total Short-Term Assets $2.665M $2.067M
Total Long-Term Assets $2.646M $2.453M
Total Assets $5.311M $4.520M
YoY Change 0.93% -43.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $403.4K
YoY Change -29.69%
Accrued Expenses $1.047M
YoY Change -10.05%
Deferred Revenue $114.5K
YoY Change -37.33%
Short-Term Debt $500.0K
YoY Change 17.65%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.535M $2.098M
YoY Change 16.11% -46.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $136.7K
YoY Change -55.02%
Total Long-Term Liabilities $136.7K
YoY Change -55.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.535M $2.098M
Total Long-Term Liabilities $136.7K
Total Liabilities $2.535M $2.251M
YoY Change 6.64% -47.05%
SHAREHOLDERS EQUITY
Retained Earnings -$83.30M -$33.23M
YoY Change 156.65% 6.52%
Common Stock $1.000K $2.180K
YoY Change -53.45% -89.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.776M $2.269M
YoY Change
Total Liabilities & Shareholders Equity $5.311M $4.520M
YoY Change 0.93% -43.37%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income -$4.289M -$769.3K
YoY Change 2760.63% -91.86%
Depreciation, Depletion And Amortization $52.77K
YoY Change -85.34%
Cash From Operating Activities -$101.1K
YoY Change -88.93%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -94.07K
YoY Change -122.13%
NET CHANGE
Cash From Operating Activities -101.1K
Cash From Investing Activities 0.000
Cash From Financing Activities -94.07K
Net Change In Cash -195.2K
YoY Change -75.31%
FREE CASH FLOW
Cash From Operating Activities -$101.1K
Capital Expenditures $0.00
Free Cash Flow -$101.1K
YoY Change -91.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
FIREFLY NEUROSCIENCE, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0000803578
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3120000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1676165
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1676165
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8476202
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8476202
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3678550
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3678550
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1215000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4289000 usd
aiff Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
0 usd
aiff Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
0 usd
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41092
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
54-1167364
dei Entity Address Address Line1
EntityAddressAddressLine1
1100 Military Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Kenmore
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
14217
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
237-6412
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
AIFF
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8503365
CY2024Q3 us-gaap Cash
Cash
1230000 usd
CY2023Q4 us-gaap Cash
Cash
2143000 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
86000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
84000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1349000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
28000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2665000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2255000 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1465000 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1109000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
386000 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
2646000 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
386000 usd
CY2024Q3 us-gaap Assets
Assets
5311000 usd
CY2023Q4 us-gaap Assets
Assets
2641000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2535000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2532000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
2535000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2532000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
86074000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76733000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83299000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76624000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2776000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
109000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5311000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2641000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
33000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
55000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
479000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
878000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
392000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1517000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
712000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
431000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
95000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
973000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
399000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2992000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
183000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4183000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
879000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4301000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
670000 usd
us-gaap Operating Expenses
OperatingExpenses
6673000 usd
us-gaap Operating Expenses
OperatingExpenses
1990000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4268000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-647000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6618000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1511000 usd
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-24000 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-3000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
-36000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
-13000 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2000 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4289000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-650000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6675000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1526000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4289000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-650000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6675000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1526000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7080897
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3678906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5828054
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3083214
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
109000 usd
aiff Stock Issued During Period Value Stock Option Warrant And Rsu Exercises
StockIssuedDuringPeriodValueStockOptionWarrantAndRsuExercises
32000 usd
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2433000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6675000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2776000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2226000 usd
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
227000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1526000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1028000 usd
CY2024Q3 aiff Stock Issued During Period Value Stock Option Warrant And Rsu Exercises
StockIssuedDuringPeriodValueStockOptionWarrantAndRsuExercises
32000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2316000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2776000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1729000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-650000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1028000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6675000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1526000 usd
us-gaap Depreciation
Depreciation
8000 usd
us-gaap Depreciation
Depreciation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2433000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
227000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
209000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
139000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
23000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
533000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
574000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
12000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-814000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
104000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-450000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4937000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1662000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
68000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
-0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
408000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
75000 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-401000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
aiff Proceeds From Issuance Of Common And Preferred Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonAndPreferredStockNetOfIssuanceCosts
945000 usd
aiff Proceeds From Issuance Of Common And Preferred Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonAndPreferredStockNetOfIssuanceCosts
2497000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
32000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3448000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4425000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2497000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-913000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
835000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2143000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1230000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
893000 usd
us-gaap Interest Paid Net
InterestPaidNet
11000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q3 us-gaap Shares Outstanding
SharesOutstanding
7472555
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83299000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76624000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4937000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1662000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><b>Use of estimates in the preparation of consolidated financial statements </b></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates.</p>
CY2024Q3 us-gaap Shares Outstanding
SharesOutstanding
7472555
CY2024Q3 aiff Prepaid Services Current
PrepaidServicesCurrent
603000 usd
CY2023Q4 aiff Prepaid Services Current
PrepaidServicesCurrent
0 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
746000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
28000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1349000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
28000 usd
CY2024Q3 aiff Prepaid Services Noncurrent
PrepaidServicesNoncurrent
1465000 usd
CY2023Q4 aiff Prepaid Services Noncurrent
PrepaidServicesNoncurrent
0 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1465000 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
-0 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2024Q3 us-gaap Finite Lived Contractual Rights Gross
FiniteLivedContractualRightsGross
1109000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-0 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1109000 usd
CY2024Q3 aiff Monthly Deposit Rate Percent Of Salary
MonthlyDepositRatePercentOfSalary
0.0833 pure
CY2024Q3 aiff Contributions To Severance Compensation Act
ContributionsToSeveranceCompensationAct
10000 usd
aiff Contributions To Severance Compensation Act
ContributionsToSeveranceCompensationAct
35000 usd
CY2023Q3 aiff Contributions To Severance Compensation Act
ContributionsToSeveranceCompensationAct
6000 usd
aiff Contributions To Severance Compensation Act
ContributionsToSeveranceCompensationAct
22000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
134333
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.77
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
335728
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.18
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
583583
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y5M4D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
aiff Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
1600 usd
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
90988
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
335728
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
185704
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.94
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
241012
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.63
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
621000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2316000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
78000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2433000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
226000 usd
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2024Q3 us-gaap Revenues
Revenues
33000 usd
CY2023Q3 us-gaap Revenues
Revenues
23000 usd
us-gaap Revenues
Revenues
55000 usd
us-gaap Revenues
Revenues
479000 usd
CY2024Q3 us-gaap Revenues
Revenues
33000 usd
CY2023Q3 us-gaap Revenues
Revenues
23000 usd
us-gaap Revenues
Revenues
55000 usd
us-gaap Revenues
Revenues
479000 usd
CY2024Q3 aiff Consulting And Subcontracting Expense
ConsultingAndSubcontractingExpense
100000 usd
CY2023Q3 aiff Consulting And Subcontracting Expense
ConsultingAndSubcontractingExpense
25000 usd
aiff Consulting And Subcontracting Expense
ConsultingAndSubcontractingExpense
177000 usd
aiff Consulting And Subcontracting Expense
ConsultingAndSubcontractingExpense
48000 usd
CY2024Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
4000 usd
CY2023Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
0 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
8000 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
0 usd
CY2024Q3 aiff Clinical Trials Expense
ClinicalTrialsExpense
0 usd
CY2023Q3 aiff Clinical Trials Expense
ClinicalTrialsExpense
0 usd
aiff Clinical Trials Expense
ClinicalTrialsExpense
0 usd
aiff Clinical Trials Expense
ClinicalTrialsExpense
19000 usd
CY2024Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
63000 usd
CY2023Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
50000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
178000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
74000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
878000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
392000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1517000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
712000 usd
CY2024Q3 us-gaap Other Selling And Marketing Expense
OtherSellingAndMarketingExpense
26000 usd
CY2023Q3 us-gaap Other Selling And Marketing Expense
OtherSellingAndMarketingExpense
1000 usd
us-gaap Other Selling And Marketing Expense
OtherSellingAndMarketingExpense
33000 usd
us-gaap Other Selling And Marketing Expense
OtherSellingAndMarketingExpense
1000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
431000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
95000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
973000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
399000 usd
CY2024Q3 aiff Rent And Maintenance Expense
RentAndMaintenanceExpense
2000 usd
CY2023Q3 aiff Rent And Maintenance Expense
RentAndMaintenanceExpense
7000 usd
aiff Rent And Maintenance Expense
RentAndMaintenanceExpense
8000 usd
aiff Rent And Maintenance Expense
RentAndMaintenanceExpense
72000 usd
CY2024Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
130000 usd
CY2023Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
1000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
201000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
42000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2992000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
183000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4183000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
879000 usd

Files In Submission

Name View Source Status
0001437749-24-035393-index-headers.html Edgar Link pending
0001437749-24-035393-index.html Edgar Link pending
0001437749-24-035393.txt Edgar Link pending
0001437749-24-035393-xbrl.zip Edgar Link pending
aiff-20240930.xsd Edgar Link pending
aiff-20240930_def.xml Edgar Link unprocessable
ex_746099.htm Edgar Link pending
ex_746100.htm Edgar Link pending
ex_746101.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
aiff-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aiff-20240930_pre.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wavd20240930d_10q.htm Edgar Link pending
wavd20240930d_10q_htm.xml Edgar Link completed
aiff-20240930_cal.xml Edgar Link unprocessable